EGFR and cancer: Interestingly, the BPA-induced inhibition of cell cycle and the EGFR/ERK pathway activation were also observed in normal prostate EPN cells, which are endowed with a wild-type (WT) AR receptor, indicating that BPA action in prostate cells is not restricted to a specific cancer cell line or linked to a specific AR mutated variants.